Olema Pharmaceuticals, Inc. (OLMA)

17.05 +0.23 (+1.37%) USD  |  NASDAQ  |  Apr 20, 12:55
More

Olema Pharmaceuticals SG&A Expense (Quarterly) : 6.864M for Dec. 31, 2025

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for OLMA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
EyePoint, Inc. 11.38M
CytomX Therapeutics, Inc. 7.36M
Corvus Pharmaceuticals, Inc. 2.278M
Protagonist Therapeutics, Inc. 11.43M
Oric Pharmaceuticals, Inc. 8.695M